14 Results for "

H1650

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "H1650" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-146130
CAS No.: 2226227-75-2
Purity:  99.22%
Target:  

Atg7 Autophagy

Research Areas:  

Cancer

ATG7-IN-2 (compound 1) is a potent ATG7 inhibitor, with an IC50 of 0.089 μM. ATG7-IN-2 inhibits autophagy marker LC3B .
loading...
    loading...
Cat. No.: HY-146131
CAS No.: 2226229-76-9
Purity:  98.17%
Target:  

Atg7 Atg8/LC3 Autophagy

Research Areas:  

Cancer

ATG7-IN-3 (Compound 18) is a potent ATG7 inhibitor with an IC50 of 0.048 μM. ATG7-IN-3 inhibits Autophagy. ATG7-IN-3 inhibits the formation of LC3B puncta. ATG7-IN-3 can be used in the researches of glioma and colon cancer .
loading...
    loading...
Cat. No.: HY-N2039
CAS No.: 80952-72-3
20(R)-Ginsenoside Rg2 shows inhibitory effects on lung cancer NCI-H1650 cells. Anti-cancer activities .
loading...
    loading...
Cat. No.: HY-147328
CAS No.: 109844-92-0
Purity:  99.43%
Target:  

Apoptosis

Research Areas:  

Cancer

LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC50=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research .
loading...
    loading...
Cat. No.: HY-W072940
CAS No.: 2088956-21-0
Target:  

Phosphatase FOXO

Research Areas:  

Cancer

Anticancer agent 7 (Example 5) modulates PP2A, and induces FOXOl transcription factor translocation to the nucleus. Anticancer agent 7 inhibits the proliferation of H1650 lung cancer cell with an IC50 of 5 μM .
loading...
    loading...
Cat. No.: HY-142094
CAS No.: 675190-57-5
Research Areas:  

Cancer

NSD3-IN-2 is a potent NSD3 inhibitor with an IC50 value of 17.97 μM. NSD3-IN-2 inhibits the growth and proliferation of non-small cell lung cancer cell lines H460, H1299 and H1650 with anti-cancer activity .
loading...
    loading...
Cat. No.: HY-170406
CAS No.: 1949840-87-2
Target:  

Bcl-2 Family

Research Areas:  

Cancer

BCL-XL-IN-3 is a cell-impermeable BCL-XL inhibitor with a Ki of 16 pM. BCL-XL-IN-3 disrupts the critical hydrogen bond network via methylation of the nitrogen atom on the P2-binding amide bond, resulting in complete loss of cellular activity against BCL-XL. BCL-XL-IN-3 can be used in non-small cell lung cancer and cancer-related research .
loading...
    loading...
Cat. No.: HY-N2039R
CAS No.: 80952-72-3
20(R)-Ginsenoside Rg2 (Standard) is the analytical standard of 20(R)-Ginsenoside Rg2. This product is intended for research and analytical applications. 20(R)-Ginsenoside Rg2 shows inhibitory effects on lung cancer NCI-H1650 cells. Anti-cancer activities .
loading...
    loading...
Cat. No.: HY-149968
CAS No.: 2911585-60-7
Research Areas:  

Cancer

LSD1-IN-25 (Compound 9j) is a potent, selective and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis .
loading...
    loading...
Cat. No.: HY-N2199
CAS No.: 2608-21-1
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK; modulates expression of Cyclin D1, CDK4, Bcl-2, Bax, cleaved caspases 3/9, MMP-9, TGF-β, STAT3, and β-catenin. Sotetsuflavone induces G0/G1 cell cycle arrest, apoptosis, autophagy, and intracellular ROS elevation, inhibits cancer cell proliferation. Sotetsuflavone inhibits tumor growth in mouse tumor xenograft models. Sotetsuflavone can be used for the research of non-small cell lung cancer and Crohn’s disease .
loading...
    loading...
Cat. No.: HY-177967
CAS No.: 1616473-67-6
Target:  

Drug Derivative

Research Areas:  

Cancer

Antitumor agent-209 (Compound 10g), a quinolone derivative, is an antitumor agent. Antitumor agent-209 can inhibit proliferation of HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650 and SK-OV-3 cells with IC50 values of 0.37, 0.58, 0.81, 0.79, 0.89, 0.78 and 0.89 μM .
loading...
    loading...
Cat. No.: HY-W098807
CAS No.: 178984-50-4
Target:  

Drug Derivative

Research Areas:  

Cancer

4-Chloro-7-ethoxyquinoline (Compound 9a), a quinolone derivative, is an anticancer agent. 4-Chloro-7-ethoxyquinoline can inhibit proliferation of HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650 and SK-OV-3 cells with IC50 values of 3.16, 3.87, 2.75, 2.66, 3.91, 3.34 and 3.46μM .
loading...
    loading...
Cat. No.: HY-172255
CAS No.: 3029505-94-7
Research Areas:  

Cancer

PI4KIII beta inhibitor 4 (Compound 16) is a selective PI4KIIIβ inhibitor with an IC50 of 0.005 μM. PI4KIIIβ inhibitor 4 induces tumor cell apoptosis, cell cycle arrest, and autophagy by inhibiting the PI3K/AKT pathway. PI4KIIIβ inhibitor 4 can be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-165503
CAS No.: 1645286-58-3
Target:  

Wnt β-catenin

Research Areas:  

Cancer

AZ1366 is an orally active tankyrase inhibitor. AZ1366 stabilizes Axin2, reduces NuMA levels, disrupts the interaction between tankyrase and NuMA, induces G2/M phase arrest, inhibits the Wnt pathway, and downregulates the expression of β-catenin-dependent genes. AZ1366 inhibits tumor growth in colorectal cancer xenograft models. AZ1366 synergistically inhibits the proliferation of non-small cell lung cancer cells, improves tumor control and significantly prolongs survival in orthotopic non-small cell lung cancer mouse models. AZ1366 is applicable to research related to colorectal cancer and non-small cell lung cancer .
loading...
    loading...
  • 1